实用临床医药杂志2013，Vol.17Issue(16)：90-91,96,3.DOI:10.7619/jcmp.201316034
贝伐单抗靶向治疗结直肠癌的安全性和有效性分析
Safety and efficacy of bevacizumab targeted therapy of colorectal cancer
张军 1彭碧文 1王亚萍 1李林均1
作者信息
- 1. 武汉大学基础医学院,湖北医药学院附属人民医院肿瘤科,湖北十堰,430072
- 折叠
摘要
Abstract
Objective To investigate the clinical efficacy of bevacizumab targeted therapy of colorectal cancer.Methods The ninety colorectal cancer patients admitted to hospital from October 2010 to October 2012 were randomly divided into control group (n =45) and treatment group (n =45).The control group was given capecitabine,and the treatment group was given bevacizumab in addition to capecitabine.The clinical efficacy,adverse reactions and levels of tumor markers of both groups were observed and compared.Results The total efficacy rate of the treatment group was significantly higher than that of the control group (P ＜ 0.05).The incidence of adverse reactions in the treatment group was similar to that of the control group (P ＞ 0.05).The levels of tissue polypeptide specific antigen,carcinoembryonic antigen,and carcinomic antigen242 of the treatment group after treatment were significantly lower than those of the control group (P ＜ 0.05).Conclusion The clinical application of bevacizumab targeted therapy of colorectal cancer can more significantly improve clinical efficacy,and the fibrinolytic system and arterial blood gas levels,relieve difficulty in breathing symptoms,and the adverse reactions can be tolerated.关键词
结直肠癌/贝伐单抗/靶向治疗Key words
colorectal cancer/ bevacizumab/ targeted therapy分类
医药卫生引用本文复制引用
张军,彭碧文,王亚萍,李林均..贝伐单抗靶向治疗结直肠癌的安全性和有效性分析[J].实用临床医药杂志,2013,17(16):90-91,96,3.
